A Phase III Randomized Study of BAY 43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 22 Mar 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sorafenib (Primary)
Indications Renal cancer; Renal cell carcinoma
Focus Adverse reactions; Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
Acronyms TARGET
Sponsors Bayer

01 Feb 2022 Results from TARGET study and four (CALGB/Alliance) clinical trials identifying predictive biomarkers of hypertension induced by these drugs using a discovery-replication approach published in the Pharmacogenomics Journal
08 Jun 2021 Results of an analysis assessing genetic predictors of sorafenib-induced toxicities from two clinical studies: ALLIANCE and TARGET presented at the 57th Annual Meeting of the American Society of Clinical Oncology
11 Oct 2016 Results assessing genetic basis of sorafenib toxicity presented at the 41st European Society for Medical Oncology Congress.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com